Aims: Cilostazol, a type phosphodiesterase inhibitor, is utilized for the treatment of intermittent claudication and is considered to have the beneficial effects against the atherogenic process. In the present study, we examined the effects of cilostazol on BH4 biosynthesis in HUVEC treated with a mixture of the pro-inflammatory cytokines IFN-and TNF-. Methods: Isolated HUVECs were grown to confluence and treated with IFN-(300 units/mL) and TNF-(300 units/mL) for 16 h in order to stimulate BH4 biosynthesis. The BH4 levels were measured by HPLC. The mRNA expression of GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme of BH4 biosynthesis, and GTPCH feedback regulatory protein (GFRP) were quantified by real-time PCR. The GTPCH protein expression was assessed by western blot analysis. GTPCH mRNA and protein. 8-bromo-cAMP (8Br-cAMP) , a cell-permeable cAMP analogue, did not reproduce the effects of cilostazol. Cilostazol did not affect the cytokine-induced inhibition of GFRP mRNA expression. Conclusions: We conclude that cilostazol inhibited cytokine-stimulated BH4 biosynthesis via a cAMP-independent mechanism in HUVEC. Our data indicate that cilostazol reduced GTPCH activity and did so by suppressing the GTPCH protein levels.
Introduction
Recent pathophysiologic observations in numerous laboratories indicate that atherosclerosis is an inflammatory disease 1) . The earliest changes in the formation of atherosclerosis take place in the endothelium. It is thus suggested that endothelial dysfunction induced by inflammatory injury leads to the promo-(GTPCH) activity 9, 10) and GTPCH protein levels 11) through the expression of mRNA for this enzyme 12) in various tissues. Lipopolysaccharide and cytokines such as interferon (IFN)-and tumor necrosis factor (TNF)-strongly induce the de novo synthesis of BH4, and concomitantly increase the de novo synthesis of nitric oxide by inducible nitric oxide synthase (iNOS) in various cells [13] [14] [15] . It is assumed that the increased production of BH4 is required to ensure a sufficient supply of the co-factor for the massive production of nitric oxide by iNOS. It is known that an excessive amount of nitric oxide in the vascular tissues is involved in the pathogenesis of various vascular diseases, such as athelosclerosis and septic shock.
In the present study, we tested the effect of cilostazol on BH4 biosynthesis as well as on nitric oxide production in HUVEC treated with pro-inflammatory cytokines. We found for the first time that cilostazol repressed the induction of BH4 without affecting nitric oxide levels in HUVEC treated with a cytokine mixture. The possible mechanism whereby cilostazol inhibited BH4 production in HUVEC is discussed.
Materials and Methods

Endothelial Cell Isolation and Culture
HUVEC were isolated by collagenase digestion from normal human umbilical cord as described previously 16) based on the method by Jaffe et al. 17) . The experimental protocol for obtaining human umbilical cord cells was approved by the institutional review board of Fujita Health University. Cells were grown to confluence in 0.2% gelatin-coated dishes (Iwaki Glass, Tokyo, Japan) containing human endothelial cell culture medium supplemented with 25 g/mL endothelial cell growth supplement (Nissui Co., Tokyo, Japan), 50 mg/mL heparin, and 100 U/mL penicillinstreptomycin at 37 in a humidified atmosphere of 5% carbon dioxide in air. Studies were conducted on cells from passages 3-6.
Assay of BH4 and GTPCH activity
Confluent HUVEC monolayers were treated with a mixture of IFN-(300 units/mL) and TNF-(300 units/mL) for 16 h in order to induce GTPCH activity. When the effects of cilostazol were being studied, the cells were simultaneously treated with the cytokine mixture and the agent. Control cultures always contained the same amount of vehicle. After treatment, the cells were sequentially harvested by trypsinization and pelleted by centrifugation. BH4 was measured by HPLC analysis according to the method by Fukushima and Nixon 18) . GTPCH activity was assayed by the quantification of D-erythro-neopterin by HPLC 19) .
Determination of mRNA Levels of GTPCH and GTPCH Feedback Regulatory Protein (GFRP)
GTPCH and GFRP mRNA levels were determined by real-time PCR using fluorescent TaqMan probes. Total RNA was extracted with a total RNA isolation kit (RNeasy Mini Kit; Qiagen, Hilden, Germany). The isolated total RNA (200 ng) was reversetranscribed using a High Capacity cDNA Reverse transcription Kit (Applied Biosystems, Foster City, CA), and then the cDNA was subjected to real-time PCR using a GeneAmp 5700 sequence detection system (Applied Biosystems). The primer and probe sets were selected from TaqMan® Gene Expression Assays (Applied Biosystems). The assay identification numbers used in this study were as follows: GTPCH, Hs00609198_m1; GFRP, Hs00193360_m1; GAPDH, Hs99999905_m1.
Determination of GTPCH Protein Expression
For measurement of GTPCH protein expression, cytoplasmic protein was extracted according to the method by Schreiber et al. 20) . A 20-g amount of protein was subjected to 10% SDS-PAGE. The separated protein bands were electrophoretically transferred to a PVDF membrane (Immun-Blot TM PVDF Membrane; Bio-Rad, Hercules, CA). GTPCH protein was probed with an antibody against a portion of the C-terminal sequence of human GTPCH (TREEFLTLIRS-5) 21) . PVDF membranes were incubated with 1000 timesdiluted anti-GTPCH antibody, followed by incubation with 5000 times-diluted horseradish peroxidaselinked anti-rabbit IgG. Immunoreactive proteins were detected with luminol as a substrate using an ECL Advance Western Blotting Detection Kit (GE Healthcare, Amersham, England). The membranes were imaged and analyzed with a Lumino Image Analyzer LAS-4000UVmini (Fujifilm, Tokyo, Japan).
Determination of STAT1 and NF-B Levels in the Nucleus
Nuclear protein was extracted as described previously 16) . In order to determine the levels of STAT1 and p65, a component of NF-B in the nucleus, we subjected 5 g of the nuclear protein to 7.5% SDS-PAGE. The separated proteins were transferred to PVDF membranes, and then incubated with antiphosphorylated (Tyr 701) STAT1 (p-STAT1) or anti-p65 polyclonal antibody, which had been diluted 500 times and 5000 times, respectively. The secondory antibodies, horseradish peroxidase-conjugated anti-rabbit antibodies, were diluted 2000 times and 15000 times, respectively. The bands of p-STAT1 and p65 were detected as described in "Determination of GTPCH Protein Expression".
Determination of cAMP and Nitric Oxide Levels
cAMP levels in KOH-neutralized HClO4 extracts of HUVEC cell pellets were determined using a commercially available enzyme immunoassay kit (Amersham Biosciences Corp., Piscataway, NJ). Nitric oxide production was assessed by determination of the stable end product of nitric oxide nitrite in the culture medium based on the Griesse reaction. The content of nitrite in the culture medium was analyzed using a Nitric Oxide Assay Kit (Assay Designs, Inc., MI, USA).
Materials
The materials used in this work, and their sources, were as follows: Cilostazol was generously provided by Otsuka Pharmaceutical Co. Ltd (Tokyo, Japan); collagenase type , penicillin-streptomycin, trypsin, 0.05% with EDTA 4Na, fetal bovine serum, and medium 199 were from Invitrogen Corp. (Grand Island, NY); PBS was from Takara Bio Inc (Shiga, Japan); IFN-and TNF-were from Pepro Tech EC (London, UK); 8-bromoadenosine 3',5'-cyclic monophosphate (8Br-cAMP) was from Sigma Chemical Co. (St. Louis, MO); the primary antibody againstactin was from Cell Signaling Technology, Inc. (Danvers, MA); anti phosphorylated (Tyr 701) STAT1 polyclonal antibody (p-STAT1) was from Santa Cruz Biotechnology Inc. (Santa Cruz,CA); anti-p65 polyclonal antibody was from Stressgen (BC, Canada); horseradish peroxidase-linked anti-rabbit IgG was from Amersham Biosciences Corp. Cilostazol was dissolved in dimethy sulfoxide. 8Br-cAMP was dissolved in water.
Statistical Analysis
The results are expressed as the means S.E.M. Data were evaluated using Student's t test for paired data and one-way analysis of variance (ANOVA) followed by Bonferroni correction for multiple data in the group. P 0.05 was considered significant.
Results
The data presented in Fig. 1A clearly indicate that cilostazol dose-dependently suppressed cytokineinduced BH4 biosynthesis in HUVEC treated with a mixture of IFN-and TNF-for 16 h. The addition of 30 M cilostazol resulted in a 44.4% decrease in cytokine-induced BH4 biosynthesis in the cells. We found that cilostazol produced a concomitant increase in the cAMP level in the HUVEC, although the stimulation was statistically significant only at concentrations of 10 M and higher (Fig. 1B) .
GTPCH is known to be the rate-limiting enzyme for BH4 biosynthesis 22) . The data presented in Fig. 2A clearly show that cilostazol (30 M) significantly reduced cytokine-stimulated GTPCH activity by 31.2%. The data illustrated in Fig. 2B show that cilostazol also inhibited the cytokine-stimulated increase in the GTPCH mRNA level. The results of Western blot analysis shown in Fig. 2C and 2D indicate that cilostazol actually decreased the expression of GTPCH protein itself (data with a wider range of molecular weight are indicated in Supplementary Fig. 1) . These results are in good agreement with the effect of cilostazol on the BH4 level ( Fig. 1A) .
Harada et al. 23) documented that GFRP inhibited GTPCH when it was bound with BH4, thus demonstrating that it mediated the feedback inhibition of BH4 biosynthesis. In the present study, we first 
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found that the expression of GFRP mRNA in cytokine-untreated HUVEC was decreased by 90.0% by the mixture of IFN-and TNF- (Fig. 3) . Cilostazol failed to affect this cytokine-induced inhibition of GFRP mRNA levels.
In order to clarify whether the inhibition by cilostazol of the cytokine-induced up-regulation of GTPCH activity originated from the increase in the cAMP level, we tested the effect of 8Br-cAMP, a cellpermeable cAMP analogue, on cytokine-induced BH4 production. 8Br-cAMP was found to exert no significant effect on BH4 levels (BH4 level at 16 h in the presence of the cytokine mixture: control, 62.3 7.8 pmoles/mg protein; 3 mM 8Br-cAMP, 52.9 4.0 pmoles/mg protein, n 4, p 0.05). Furthermore, 8Br-cAMP (3 mM) failed to reproduce any effect of cilostazol on GTPCH activity, mRNA and protein expression ( Fig. 2) . 8Br-cAMP (3 mM) also did not influence cytokine-induced inhibition of GFRP mRNA levels (Fig. 3) .
We conducted experiments to see whether cilostazol exerts significant effects on STAT1 levels as well as NF-B levels in HUVEC nuclei by Western blot analysis. Cilostazol failed to affect the cytokineinduced accumulation of STAT1 and NF-B in HUVEC nuclei. Negative results of the experiments conducted with cilostazol are not shown.
In the present study, cilostazol did not affect the accumulation of nitrite, the stable end product of NO, in culture medium (nitrite levels at 16 h in the presence of cytokine mixture: control, 6.7 1.0 M, 30 M cilostazol, 6.9 1.0 M, n 3). 
Discussion
It is conceivable that the accelerated production of BH4 in endothelial cells under inflammatory stimulation is a manifestation of endothelial dysfunction during the pathogenesis of atherosclerosis and is pivotal for the progress of atherosclerosis. BH4 is synthesized de novo from GTP, and the first and rate-limiting step in the biosynthetic pathways is catalyzed by GTPCH 22) . The present data strongly suggest that the cytokine mixture stimulated GTPCH activity in HUVEC at least by 2 mechanisms: the enhancement of GTPCH protein levels due to increased GTPCH mRNA expression, and the obliteration of GFRP mRNA expression. The new and important finding in the present study is that cilostazol significantly inhibited cytokine-induced BH4 biosynthesis in HUVEC. Our results clearly indicate that cilostazol blocked cytokine-stimulated GTPCH activity along with inhibition of the GTPCH protein level as well as GTPCH mRNA expression. Cilostazol did not release the suppression by the cytokine mixture of the expression of GFRP mRNA in HUVEC. We thus conclude that the cilostazol-mediated inhibition of cytokine-induced BH4 production in HUVEC was principally exerted through the inhibition of GTPCH activity due to the suppression of GTPCH mRNA expression and the consequent reduction in GTPCH enzyme levels in HUVEC. We also found in the present study that the inhibition of BH4 biosynthesis by cilostazol was accompanied by the accumulation of intracellular cAMP in cytokine-stimulated HUVEC. Nevertheless, we observed that exogenously applied 8Br-cAMP did not reproduce any effects of cilostazol on BH4 production, GTPCH activity, GTPCH mRNA level or GTPCH protein expression in the present experimental condition. We also observed that forskolin did not affect BH4 levels in cytokine-stimulated HUVEC (data not shown). It is thus suggested that cilostazol is not likely to inhibit BH4 biosynthesis via a cAMP mediated intracellular signal transduction system in HUVEC. Huang et al. 24) reported that both STAT1 and NF-B were indispensable for the induction of GTPCH in HUVEC. Otsuki et al. 8) reported that cilostazol repressed vascular cell adhesion molecule-1 gene transcription in cultured HUVEC by inhibiting NF-B binding to its recognition sequence. Recently, Hattori et al. 25) documented that cilostazol inhibited cytokine-induced NF-B activation via AMP-activated protein kinase activation in HUVEC; however, our results indicated that cilostazol failed to affect the cytokine-induced accumulation of STAT1 and NF-B in HUVEC nuclei.
In the present study, we found that cilostazol did not affect nitric oxide production in cytokine-stimulated HUVEC, although it caused a significant inhibition of BH4 production. Further study needs to be carried out to elucidate the biological significance and the mechanism of cilostazol action. 
